Showing 3491-3500 of 5910 results for "".
- Algorithm Compares Risk of Cancelled Ophthalmology Appointments Against COVID-19https://modernod.com/news/algorithm-compares-risk-of-cancelled-ophthalmology-appointments-against-covid-19/2478075/The COVID-19 pandemic has forced many ophthalmologists across the US to cancel potentially necessary eye examinations with patients since March. A team, led by Nikhil K. Bommakanti, MD, W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, developed a f
- Moderna Loses US Patent Challenge That Could Affect COVID-19 Vaccinehttps://modernod.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the
- NowRx, Medly Pharmacy Land New Funding as Demand for Digital Pharmacies Growshttps://modernod.com/news/nowrx-medly-pharmacy-land-new-funding-as-demand-for-digital-pharmacies-grows/2478052/Digital pharmacy startups taking on industry giants CVS and Walgreens are securing sizable sums of money from investors, according to a FierceHealthcare
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- OCT Angiography Demonstrates Retinal Involvement in Amblyopiahttps://modernod.com/news/oct-angiography-demonstrates-retinal-involvement-in-amblyopia/2478003/Optical coherence tomography angiography (OCT-A) could play a role in diagnosing and understanding the pathogenesis of amblyopia, researchers in Hong Kong report, according to a Reuters report. “Our study, utilizing high-reso
- Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-Specific Antibody Therapeutics for Cancer and Retinal Diseaseshttps://modernod.com/news/numab-therapeutics-and-boehringer-ingelheim-enter-into-collaboration-to-develop-multi-specific-antibody-therapeutics-for-cancer-and-retinal-diseases/2478000/Boehringer Ingelheim and Numab Therapeutics announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen for the Treatment of Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reinitiates-patient-enrollment-in-clinical-study-of-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477911/Lineage Cell Therapeutics announced that it has restarted patient enrollment in a phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD),
- FAH Demands More Time For Providers to Repay Advance Medicare Payments Due Soonhttps://modernod.com/news/fah-demands-more-time-for-providers-to-repay-advance-medicare-payments-due-soon/2477909/The Federation of American Hospitals is imploring Medicare to give providers more time to repay advanced Medicare loans sent out to help providers facing a financial crisis from COVID-19, according to a FierceHealthcare